Background: Traditional Tuberculosis (TB) treatments and analgesic therapies are often associated with resistance and poor patient compliance, highlighting the need for improved delivery systems. SLNPs, with their lipid matrix encapsulation, offer promising solutions to these challenges, making them valuable tools for enhancing TB treatment and analgesic effects. Objective: The primary aim of this review was to assess and investigate the potential of SLNPs. This included evaluating their effectiveness in improving the Bioavailability (BA) and therapeutic results of anti-TB medications, along with their capacity to deliver prolonged analgesic effects. The formulation methods and applications of SLNPs have the potential to transform the treatment of tuberculosis and pain management. Methods: This review utilized multiple electronic databases, including PubMed, Scopus, official websites, Google Scholar, Google Patent, and ResearchGate, to gather original review articles. Publications from the last 15 years, from August 31, 2009 to August 31, 2024, were selected for data compilation. The initial two authors conducted the selection, extraction, and review of the articles to compile the complete dataset. Results: Over 70 studies, along with an additional 30, were selected for the review. These findings underscore the ability of SLNPs to overcome the obstacle of conventional drug therapies, supporting their application in TB treatment and pain management. Conclusion: Most studies suggest that SLNPs represent a significant advancement in drug delivery, offering a modern formulation approach that can enhance TB treatment and provide effective analgesic relief. However, the extent of these benefits may be underreported.
Mishra et al. (Sun,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: